.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Queensland Health
Teva
Dow
Merck
Express Scripts
Argus Health
Johnson and Johnson
Novartis
Deloitte

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204671

« Back to Dashboard
NDA 204671 describes SOVALDI, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the SOVALDI profile page.

The generic ingredient in SOVALDI is sofosbuvir. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir profile page.

Summary for NDA: 204671

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:9
Formulation / Manufacturing:see details

Pharmacology for NDA: 204671

Ingredient-typeNucleoside Analog
Mechanism of ActionRNA Replicase Inhibitors

Suppliers and Packaging for NDA: 204671

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOVALDI
sofosbuvir
TABLET;ORAL 204671 NDA Gilead Sciences, Inc. 61958-1501 61958-1501-1 28 TABLET, FILM COATED in 1 BOTTLE (61958-1501-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength400MG
Approval Date:Dec 6, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 6, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Apr 7, 2020
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Apr 7, 2024
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Dow
US Department of Justice
QuintilesIMS
Queensland Health
Merck
Teva
Argus Health
UBS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot